ClinicalTrials.gg
Active, not recruitingNCT05662319ATLAS-NEOUpdated Feb 4, 2026

A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

A Phase 3 interventional study of Fitusiran and Clotting factor concentrates (CFC) or bypassing agents (BPA) in Hemophilia, sponsored by Sanofi. Active, not recruiting at 50 sites in 17 countries. Open to male participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
91
Allocation
Not applicable
Ages
12 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing fitusiran in Hemophilia A — 2 open to participants now, 3 under way, 2 of them phase 3. fitusiran · Hemophilia A.

Enrollment
3rd of 10
91 · median 70
Started
2023
the only one that year
Phase 3
6 of 10
1 open now
Registered
8th of 10
by date
Lead sponsor
4 of 10
Sanofi

Among the 10 studies testing fitusiran in Hemophilia A, this one is the 3rd largest by enrollment, is the only one that started in 2023, is one of 6 in phase 3, and was the 8th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

2 of the 10 studies testing fitusiran in Hemophilia A are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fitusiran

fitusiran: first FDA approval 2025 (QFITLIA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing fitusiran in Hemophilia A, or all of them as a file.
02

Study summary

This is a multicenter, multinational, open-label, one-way cross-over, Phase 3, single-arm study for treatment of hemophilia.

The purpose of this study is to measure the frequency of treated bleeding episodes with fitusiran in male adult and adolescent (≥12 years old) participants with hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX who have switched from their prior standard of care treatment.

The total study duration will be up to approximately 50 months (200 weeks, 1 study month is equivalent to 4 weeks) and will include:

  • A screening period up to approximately 60 days,
  • A standard of care (SOC) period of approximately 6 study months (24 weeks),
  • A fitusiran treatment period of approximately 36 study months (144 weeks),
  • An antithrombin (AT) follow-up period of approximately 6 study months (24 weeks) but may be shorter or longer depending on individual participants AT recovery.

The frequency for telephone visits will be approximately every 2 weeks. For site visits the frequency will be approximately every 8 weeks during the SOC period and approximately every 4 weeks during the fitusiran treatment period. If applicable and if allowed by local regulation, home and/or remote visits may be conducted during the study

03

Conditions studied

  • Hemophilia

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of severe congenital hemophilia A or B (FVIII \<1% or FIX level ≤2%) as evidenced by a central laboratory measurement at screening or documented medical record evidence.
  • For participants currently not on prophylaxis (CFC or BPA on-demand): A minimum of 4 bleeding episodes requiring BPA (inhibitor participants) or CFC (non-inhibitor participants) treatment within the last 6 months prior to screening.
  • Willing and able to comply with the study requirements and to provide written and assent in the case of participants under the age of legal consent, per local and national requirements

Exclusion criteria

Exclusion Criteria:

  • Known co-existing bleeding disorders other than congenital hemophilia A or B
  • History of arterial or venous thromboembolism, not associated with an indwelling venous access
  • History of intolerance to SC injection(s).
  • Current participation in immune tolerance induction therapy (ITI)
  • Prior gene therapy
  • Current or prior participation in a fitusiran trial
  • Current or prior participation in a gene therapy trial
  • Received an drug or device within 30 days prior to the screening visit or within 5 half-lives of the investigational drug (or device) prior to the screening visit, whichever is longer
  • Presence of liver disease AT activity \<60% at Screening
  • Co-existing thrombophilic disorder
  • virus antibody positive, except participants who have negative Hepatitis C viral load and no evidence of cirrhosis
  • Presence of acute hepatitis, ie, hepatitis A, hepatitis E.
  • Presence of acute or chronic infection
  • Known to be positive with \<200 cells/μL.
  • Reduced renal function The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    All participants

    In standard of care (SOC) period, participants will receive on-demand or prophylactic treatment with clotting factor concentrates (CFCs) or bypassing agents (BPAs) for 6 months (from Day -168 to Day -1). In fitusiran treatment period, participants will receive subcutaneous fitusiran prophylaxis once every other month (Q2M) or once monthly (QM) for 36 months (from Day 1 to Day 1009). In case of bleeding events participants will receive IV CFCs or BPAs. Participants may receive Antithrombin concentrate (ATIIIC) as rescue medicine. .

    Drug: Fitusiran · Drug: Clotting factor concentrates (CFC) or bypassing agents (BPA) · Drug: Antithrombin concentrate (ATIIIC)

Interventions

  • Pharmaceutical form: Solution for injection Route of administration: Subcutaneous (SC)

  • DrugClotting factor concentrates (CFC) or bypassing agents (BPA)

    * Coagulation factor VIII (ATC code: B02BD02) * Coagulation factor IX (ATC code: B02BD04) * Coagulation factor VIIa (ATC code: B02BD08) * Factor VIII inhibitor bypassing activity (ATC code: B02BD03) Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)

  • DrugAntithrombin concentrate (ATIIIC)

    Antithrombin III (ATC code: B01AB02) Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)

06

What researchers measure

Primary outcomes

  1. Annualized bleeding rate (ABR) in the fitusiran primary efficacy period

    A bleeding episode is defined as any occurrence of hemorrhage that requires administration of CFCs or BPAs, e.g., hemarthrosis, muscle, or mucosal bleeding.

    Time frame: Day 169 to Day 505 (since the first dose of fitusiran)

Secondary outcomes

  1. Annualized bleeding rate (ABR) while on fitusiran prophylaxis in the fitusiran primary efficacy period and ABR while on prophylaxis standard of care (SOC) in the SOC period

    A bleeding episode is defined as any occurrence of hemorrhage that requires administration of CFCs or BPAs, e.g., hemarthrosis, muscle, or mucosal bleeding.

    Time frame: Day 169 to Day 505 (primary efficacy period) and Day -168 to Day -1 (SOC period)

  2. Annualized bleeding rate (ABR) while on fitusiran prophylaxis in the fitusiran primary efficacy period and ABR while on on-demand standard of care (SOC) in the SOC period

    A bleeding episode is defined as any occurrence of hemorrhage that requires administration of CFCs or BPAs, e.g., hemarthrosis, muscle, or mucosal bleeding.

    Time frame: Day 169 to Day 505 (primary efficacy period) and Day -168 to Day -1 (SOC period)

  3. Annualized spontaneous bleeding rate in the fitusiran primary efficacy period and in the SOC period

    A bleeding episode is defined as any occurrence of hemorrhage that requires administration of CFCs or BPAs, e.g., hemarthrosis, muscle, or mucosal bleeding. A spontaneous bleeding episode is a bleeding event that occurs for no apparent or known reason, particularly into the joints, muscles, and soft tissues.

    Time frame: Day 169 to Day 505 (primary efficacy period) and Day -168 to Day -1 (SOC period)

  4. Annualized joint bleeding rate in the fitusiran primary efficacy period and in the SOC period

    A bleeding episode is defined as any occurrence of hemorrhage that requires administration of CFCs or BPAs, e.g., hemarthrosis, muscle, or mucosal bleeding. A joint bleeding episode is characterized by an unusual sensation in the joint ("aura") in combination with 1) increasing swelling or warmth over the skin over the joint, 2) increasing pain, or 3) progressive loss of range of motion or difficulty in using the limb as compared with baseline.

    Time frame: Day 169 to Day 505 (primary efficacy period) and Day -168 to Day -1 (SOC period)

  5. Change in Haem-A-QOL physical health score and total score during SOC and during fitusiran prophylaxis

    The Haem-A-QoL will be provided to participants ≥17 years of age and includes 46 items contributing to 10 QoL domains (physical health, feelings, view of yourself, sports and leisure, work and school, dealing with hemophilia, treatment, future, family planning, partnership, and sexuality). Scoring for each item is based on a 5-point Likert scale (never, rarely, sometimes, often, and all the time), and higher scores represent greater impairment.

    Time frame: Day 1 (D1) to Day 505, and from D1 to Day 1009, and during SOC from Day-168 to D-1

  6. Annualized bleeding rate (ABR) in the fitusiran 18-month efficacy period

    A bleeding episode is defined as any occurrence of hemorrhage that requires administration of CFCs or BPAs, e.g., hemarthrosis, muscle, or mucosal bleeding.

    Time frame: Day 1 to Day 505

  7. Annualized bleeding rate (ABR) in the fitusiran 36-month treatment period

    A bleeding episode is defined as any occurrence of hemorrhage that requires administration of CFCs or BPAs, e.g., hemarthrosis, muscle, or mucosal bleeding.

    Time frame: Day 1 to Day 1009

  8. Annualized weight-adjusted consumption of CFC/BPA

    All CFC or BPA doses (including doses per kg body weight) administered during the study treatment will be recorded

    Time frame: Day -168 until Day 1009

  9. Number of participants with adverse events

    All AEs (serious or nonserious) will be collected from the signing of the informed consent form (ICF) until last AT follow up visit.

    Time frame: Date of signed ICF (Day -228 to Day -169) until last visit (approximately 50 months after date of signed ICF)

07

Study locations

50 sites
  • Center for Inherited Blood Disorders (CIBD) Site Number : 8400012
    Orange, California 92868-4306, United States
  • M Health Fairview University of Minnesota Medical Center - West Bank- Site Number : 8400016
    Minneapolis, Minnesota 55454, United States
  • Hackensack University Site Number : 8400009
    Hackensack, New Jersey 07601, United States
  • Northwell Health Hemostasis and Thrombosis Center Site Number : 8400015
    New Hyde Park, New York 11040, United States
  • University Hospitals of Cleveland Site Number : 8400001
    Cleveland, Ohio 44106, United States
  • UPMC Children's Hospital of Pittsburgh-4401 Penn Ave Site Number : 8400017
    Pittsburgh, Pennsylvania 15224-1334, United States
  • Children's Medical Center Dallas- Site Number : 8400018
    Dallas, Texas 75235, United States
  • Gulf States Hemophilia and Thrombophilia Center- Site Number : 8400002
    Houston, Texas 77030, United States
  • Investigational Site Number : 1240001
    Hamilton, Ontario L8N 3Z5, Canada
  • Investigational Site Number : 1240002
    Hamilton, Ontario L8N 3Z5, Canada
  • Investigational Site Number : 1240004
    Toronto, Ontario M5G 1X8, Canada
  • Investigational Site Number : 1560003
    Beijing, 100045, China
  • Investigational Site Number : 1560001
    Guangzhou, 510515, China
  • Investigational Site Number : 1560002
    Jinan, 250013, China
  • Investigational Site Number : 2500003
    Le Kremlin-Bicêtre, 94275, France
  • Investigational Site Number : 2500002
    Lille, 59037, France
  • Investigational Site Number : 2500001
    Paris, 75015, France
  • Investigational Site Number : 2760001
    Berlin, 10249, Germany
  • Investigational Site Number : 2760002
    Hamburg, 20246, Germany
  • Investigational Site Number : 3000001
    Athens, 115 27, Greece
  • Investigational Site Number : 3000002
    Athens, 11527, Greece
  • Investigational Site Number : 3560004
    Bangalore, 560 034, India
  • Investigational Site Number : 3560007
    Bhubaneswar, 751019, India
  • Investigational Site Number : 3560001
    Pune-411011, 411 011, India
  • Investigational Site Number : 3560006
    Punjab, 141008, India
  • Investigational Site Number : 3560003
    Vellore, 632004, India
  • Investigational Site Number : 3800003
    Rozzano, Milano 20089, Italy
  • Investigational Site Number : 3800001
    Milan, 20122, Italy
  • Investigational Site Number : 3920003
    Nagoya, Aichi-ken 4668560, Japan
  • Investigational Site Number : 3920001
    Kashihara-shi, Nara 634-8522, Japan
  • Investigational Site Number : 3920002
    Saitama-shi, Saitama 330-8777, Japan
  • Investigational Site Number : 4840002
    Monterrey, Nuevo León 64460, Mexico
  • Investigational Site Number : 4840004
    Chihuahua City, 31000, Mexico
  • Investigational Site Number : 4840001
    Veracruz, 91900, Mexico
  • Investigational Site Number : 6160002
    Krakow, Lesser Poland Voivodeship 30-688, Poland
  • Investigational Site Number : 6160004
    Lodz, Lódzkie 93-510, Poland
  • Investigational Site Number : 6160001
    Warsaw, Masovian Voivodeship 02-776, Poland
  • Investigational Site Number : 6820002
    Jeddah, 21423, Saudi Arabia
  • Investigational Site Number : 7100003
    Johannesburg, 1501, South Africa
  • Investigational Site Number : 7100001
    Parktown, 2193, South Africa
  • Investigational Site Number : 4100001
    Seoul, Seoul-teukbyeolsi 03722, South Korea
  • Investigational Site Number : 4100002
    Seoul, Seoul-teukbyeolsi 05278, South Korea
  • Investigational Site Number : 7240002
    A Coruña, A Coruña [La Coruña] 15006, Spain
  • Investigational Site Number : 7240003
    Zaragoza, 50009, Spain
  • Investigational Site Number : 1580001
    Taipei, 100, Taiwan
  • Investigational Site Number : 1580003
    Taipei, 11031, Taiwan
  • Investigational Site Number : 7920002
    Adana, 01130, Turkey (Türkiye)
  • Investigational Site Number : 7920004
    Akdeniz, 07059, Turkey (Türkiye)
  • Investigational Site Number : 7920001
    Çapa, 34390, Turkey (Türkiye)
  • Investigational Site Number : 7920003
    Izmir, TR-35100, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Mar 2027, 49 months after the start.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 49 months is above that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2022
First posted
Dec 22, 2022
StartActual
Feb 1, 2023
Primary completionEst.
Mar 25, 2027
CompletionEst.
Jan 25, 2029
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05662319
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 22, 2022
Start date
Feb 1, 2023
Primary completion
Mar 25, 2027 (estimated)
Completion
Jan 25, 2029 (estimated)
Last update
Feb 4, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fitusiran

Start the discussion